PSMB5 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL253626	1.00	20/20
SCHEMBL253622	0.83	20/20
SCHEMBL252153	0.81	20/20
SCHEMBL253976	0.75	20/20
SCHEMBL254186	0.69	20/20
SCHEMBL252817	0.67	19/20
SCHEMBL84961	0.89	18/20
SCHEMBL254225	0.75	18/20
SCHEMBL84929	0.73	18/20
SCHEMBL253646	0.70	18/20
Carfilzomib (SCHEMBL85165)	1.00	17/20
SCHEMBL84978	0.84	17/20
SCHEMBL85532	0.69	17/20
Bortezomib (SCHEMBL3676)	1.00	16/20
Marizomib (SCHEMBL151667)	1.00	16/20
Bortezomib (SCHEMBL192129)	1.00	16/20
Cinnabaramide A (SCHEMBL208595)	1.00	16/20
Marizomib (SCHEMBL209546)	1.00	16/20
SCHEMBL84543	0.79	16/20
SCHEMBL234139	0.71	16/20

Clinical trials — most relevant to PSMB5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease	PHASE4	UNKNOWN
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer	PHASE2	COMPLETED
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma	PHASE2	COMPLETED
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors	PHASE2	COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Biologic Correlative Taxotere/AC	PHASE2	COMPLETED
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy	PHASE2	NOT_YET_RECRUITING
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma	PHASE2	WITHDRAWN
Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma	PHASE2	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma	PHASE1	COMPLETED
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer	PHASE1	COMPLETED
Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery	PHASE1	COMPLETED
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM	PHASE1	WITHDRAWN
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma	PHASE1	COMPLETED
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma	PHASE1	COMPLETED
Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma	PHASE1	COMPLETED
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment	nan	UNKNOWN
Cardiovascular Complications of Carfilzomib Treatment	nan	UNKNOWN
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS)	nan	UNKNOWN
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract	nan	UNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)	nan	UNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Relationship Between Nutritional State and Respiratory Muscle Weakness in Adult Patients With Bronchietasis	nan	UNKNOWN
Analysis by Clinical Mass Spectrometry of Bloodstains	nan	COMPLETED
Cholesterol and Statin in Healthy Adults	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PSMB5 binder may also engage these)

Protein	Name	Similarity
Q5R8S2	—	1.000	Q5R8S2 →
O55234	—	0.999	O55234 →
P28075	—	0.999	P28075 →
Q32KL2	—	0.998	Q32KL2 →
P28064	—	0.995	P28064 →
Q3T112	—	0.993	Q3T112 →
P28063	—	0.990	P28063 →
Q9LIP2	—	0.990	Q9LIP2 →
Q5W416	—	0.990	Q5W416 →
PSMB8	Proteasome subunit beta type-8	0.990	landscape →
O24361	—	0.989	O24361 →
O23717	—	0.989	O23717 →
Q4KM35	—	0.988	Q4KM35 →
P30656	—	0.988	P30656 →
Q54BC8	—	0.987	Q54BC8 →
P34065	—	0.987	P34065 →
B1W306	—	0.986	B1W306 →
PSMB7	Proteasome subunit beta type-7	0.985	landscape →
Q3T0T1	—	0.985	Q3T0T1 →
Q09841	—	0.985	Q09841 →
P30655	—	0.985	P30655 →
A1XQU1	—	0.985	A1XQU1 →
Q3T0X5	—	0.984	Q3T0X5 →
P70195	—	0.984	P70195 →
Q5REN2	—	0.984	Q5REN2 →
Q2J9Q3	—	0.984	Q2J9Q3 →
C7MWV7	—	0.984	C7MWV7 →
C9Z4D0	—	0.984	C9Z4D0 →
Q82JE3	—	0.984	Q82JE3 →
A8M2A3	—	0.984	A8M2A3 →